Physicians at the clinic are able to adjust the number of shots or frequency depending on your health goals
Table 5: Changes from Week 26 Baseline to Week 52 in IGF-1, IGFBP-3, Weight, and Waist Circumference by Treatment Group (Intent-To-Treat Population with Last Observation Carried Forward) Patients treated with a 2 mg dose of EGRIFTA (1 mg/formulation) for 52 weeks (T-T group) showed no change between Weeks 26 and 52 in mean trunk fat (increase of 0.1 kg in Study 1 and decrease of 0.5 kg in Study 2, respectively, compared with an increase of 1.4 kg in patients in the T-P group in Study 1 and an increase of 1.09 kg in Study 2, respectively) nor was there a change from Week 26 baseline in mean lean body mass (decrease of 0.1 kg in Study 1 and increase of 0.1 kg in Study 2, respectively, compared with a decrease of 1.8 kg in patients in the T-P group in Study 1 and a decrease of 1.7 kg in Study 2, respectively)
doi:10.2106/JBJS.I.01286 (5) Safran O, Schroeder J, Bloom R, Weil Y, Milgrom C
Erickson MA, Banks WA (2013) Bloodbrain barrier dysfunction as a cause and consequence of Alzheimers disease
Glutathione IV Therapy is a potential option to achieve lighter, brighter skin